Beijing Konruns Pharmaceutical Co.,Ltd. (SHA:603590)

Market Cap	4.70B -53.5%
Revenue (ttm)	917.99M +9.5%
Net Income	168.68M +274.4%
EPS	1.06 +270.4%
Shares Out	157.53M
PE Ratio	28.16
Forward PE	26.41
Dividend	0.35 (1.17%)
Ex-Dividend Date	Jul 8, 2026

Volume	2,780,700
Open	30.03
Previous Close	29.84
Day's Range	30.00 - 30.95
52-Week Range	27.33 - 65.50
Beta	0.40
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 26, 2026

About SHA:603590

Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. The company offers agkistrodon halys hemocoagulase under Suling trade name. It is also involved in the development of drug candidates, including ZY5301 that is in phase 3 clinical trials for the treatment of chronic pelvic pain in sequelae of pelvic inflammatory disease; and KC1036, which is in phase 2 clinical trial for the treatment of solid tumors. The company was founded in 2003 and is headqu...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 793
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603590

Financial Performance

In 2025, SHA:603590's revenue was 915.12 million, an increase of 10.87% compared to the previous year's 825.40 million. Earnings were 165.97 million, an increase of 293.13%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 4, 2026

Data Sources Report a data error